The company operates a commercial-stage gene therapy business for severe genetic diseases with completed acquisition by funds managed by Carlyle and SK Capital. Bluebird's competitive advantage lies in its FDA-approved gene therapy portfolio, though the company faces challenges related to manufacturing scale-up, payer partnerships, and patient access infrastructure needed to commercialize these transformative therapies at scale.
Cyborg Score Rationale
Bluebird bio faces significant operational and financial challenges despite having validated, FDA-approved gene therapies. The company's minimal market capitalization ($48.67M), negative margins (-192.4% profit margin), and pending private acquisition indicate acute financial distress and limited near-term commercial momentum.
Top Insights
The company generates $103.95M in trailing twelve-month revenue with -192.4% profit margin and revenue growth of +108.4% quarter-over-quarter, indicating commercial traction offset by unsustainable cost structure
Amended merger agreement with Carlyle and SK Capital offers stockholders either $3.00 per share plus a $6.84 CVR contingent on net sales milestones, or $5.00 per share in cash (as of May 2025)
Clinical pipeline includes HGB-205, HGB-206, HGB-210 for sickle cell disease treatment and HGB-204, HGB-205, HGB-207, HGB-212 for β-thalassemia, with strategic collaborations with Orchard Therapeutics, Forty Seven, and Magenta Therapeutics
Stock underwent 1-20 reverse split on December 13, 2024, a capital restructuring move typically signaling financial distress
Named Competitors
CRISPR Therapeutics — CRISPR-based gene editing for genetic diseases
Vertex Pharmaceuticals — Cell and gene therapy developer